Want to see GB:POLB full AI Analyst Report?
POLB Stock Chart & Stats
3.55 p
0.24 p(5.04%)
At close: 4:00 PM EST
3.55 p
0.24 p(5.04%)
Day’s Range― - ―
52-Week Range2.50 p - 9.00 p
Previous CloseN/A
Volume846.29K
Average Volume (3M)1.12M
Market Cap
£47.59M
Enterprise Value46.23M
Total Cash (Recent Filing)£7.71M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding705,103,760
10 Day Avg. Volume836,211
30 Day Avg. Volume1,116,415
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Potent Target Engagement In LPS ChallengeRobust cytokine suppression in a controlled human LPS challenge is a durable scientific signal that validates the drug’s mechanism and de-risks early development. Strong biomarker efficacy supports regulatory dialogue, improves partner interest, and raises the probability that later oncology CRS studies will show meaningful pharmacology.
Regulatory Wins And Long Patent CoverageOrphan designation and a patent estate extending to 2044 provide structural exclusivity and patent-backed protection, enhancing long-term commercial upside. These durable IP and regulatory positions strengthen bargaining power with partners, create barriers to entry, and increase the value of future licensing or commercialization deals.
TOPICAL Trial Readiness And Industry CollaborationHaving regulatory approval, sites, an appointed CRO and an industry supplier in place materially reduces execution risk and shortens timelines. Free supply of teclistamab and established trial infrastructure improve cost efficiency, credibility with partners and speed to interim data, strengthening the company’s development and licensing prospects.
Bears Say
Pre-revenue With Sustained Operating LossesPersistent pre-revenue status and multi-year operating losses mean the business cannot self-fund development from operations. Sustained negative profitability increases reliance on external capital, heightens dilution risk for shareholders, and limits strategic flexibility to scale programs without partner funding.
Equity Erosion And Finite Cash Runway Into 2027Material equity erosion and a limited cash runway concentrate financing risk: additional fundraising or licensing is likely before pivotal late‑stage work. That structural financing need can force dilutive raises or suboptimal partnership terms, constraining long-term development autonomy and shareholder value retention.
Small, Open-label TOPICAL Study Limits Definitive ProofA small, single-arm open-label design reduces evidentiary weight for regulators and payers, likely requiring larger randomized trials to secure approval or favorable reimbursement. This structural limitation can prolong development timelines, increase required capital and weaken negotiating leverage with partners.
Poolbeg Pharma Ltd. News
POLB FAQ
What was Poolbeg Pharma Ltd.’s price range in the past 12 months?
Poolbeg Pharma Ltd. lowest share price was 2.50 p and its highest was 9.00 p in the past 12 months.
What is Poolbeg Pharma Ltd.’s market cap?
Poolbeg Pharma Ltd.’s market cap is £47.59M.
When is Poolbeg Pharma Ltd.’s upcoming earnings report date?
Poolbeg Pharma Ltd.’s upcoming earnings report date is Sep 08, 2026 which is in 69 days.
How were Poolbeg Pharma Ltd.’s earnings last quarter?
Poolbeg Pharma Ltd. released its earnings results on Apr 28, 2026. The company reported -0.005 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.005 p.
Is Poolbeg Pharma Ltd. overvalued?
According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued.
Does Poolbeg Pharma Ltd. pay dividends?
Poolbeg Pharma Ltd. does not currently pay dividends.
What is Poolbeg Pharma Ltd.’s EPS estimate?
Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poolbeg Pharma Ltd. have?
Poolbeg Pharma Ltd. has 705,103,760 shares outstanding.
What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?
Poolbeg Pharma Ltd. reported an EPS of -0.005 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.371%.
Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?
Currently, no hedge funds are holding shares in GB:POLB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Poolbeg Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.05%
12-Months-Change
Fundamentals
Return on Equity
-55.47%
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Open Orphan Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---